Oncotarget

Research Papers:

Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells

Peng-Yuan Zhuang, Ke-Wei Zhang, Jian-Dong Wang, Xue-Ping Zhou, Ying-Bin Liu, Zhi-Wei Quan and Jun Shen _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:77915-77927. https://doi.org/10.18632/oncotarget.20946

Metrics: PDF 1419 views  |   HTML 1963 views  |   ?  


Abstract

Peng-Yuan Zhuang1,*, Ke-Wei Zhang1,*, Jian-Dong Wang1, Xue-Ping Zhou1, Ying-Bin Liu1, Zhi-Wei Quan1 and Jun Shen1

1Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Jun Shen, email: [email protected]

Keywords: hepatocellular carcinoma, IL-6, TALEN

Received: June 05, 2017    Accepted: July 26, 2017    Published: September 15, 2017

ABSTRACT

Purpose: To determine the exact effect of Interleukin-6 (IL-6) on tumor cell proliferation, apoptosis, invasion, and anti-cancer therapy in hepatocellular carcinoma (HCC).

Experimental Design: IL-6 was disrupted by transcription activator-like effector nucleases (TALEN) in HCCLM3 cells, and was used to evaluate the role of IL-6 on tumor cell proliferation, apoptosis, invasion and key signaling pathways involved in sorafenib and/or IFNα therapy.

Results: IL-6 has no direct effect on cell proliferation and invasion but promotes cell apoptosis and up-regulate IL-33 and VEGF-A expression. IL-6 could attenuate the anti-proliferation effect by sorafenib and combination therapy but facilitate the pro-apoptosis of the combination therapy and augment the pro-invasive effect induced by single treatment. IL-6 could down-regulate p-STAT3, however up-regulate the p-MEK/p-ERK and NF-kB/iNOS expression, and it also facilitated the promotion on p-JAK2 and p-MEK/p-ERK by either sorafenib or IFN-α. in vivo study, IL-6 significantly promotes tumor growth. The combination treatment showed the highest inhibition on tumor growth which is derived from HCCLM3-IL6(-) cells.

Conclusions: IL-6 has no direct effect on cell proliferation and invasion but promotes tumor cell apoptosis in vitro study. Sorafenib and combination therapies are suitable for HCC cells with low or no IL-6 expression confirmed in vivo study.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20946